

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jinxin Fertility Group Limited

錦欣生殖醫療集團有限公司*

(Incorporated under the laws of the Cayman Islands with limited liability)

(Stock Code: 1951)

UPDATE ON IMPLEMENTATION OF THE SHAREHOLDER RETURN PLAN

This announcement is made by Jinxin Fertility Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 Laws of Hong Kong).

In March 2026, the Company announced a shareholder return plan for the three financial years from 2026 to 2028 (the “**Shareholder Return Plan**”), pursuant to which the Company aims to deliver a total shareholder return of an amount equal to 50% to 80% of its non-IFRS adjusted EBITDA for the relevant financial year, with reference to the Company’s normalized free cash flow through, among others, share repurchases and dividend distributions as determined by the Board at its discretion. The Board has also resolved to repurchase shares of the Company (“**Shares**”) up to RMB300 million in the open market within a period of 12 months.

Over the past 12 months and up to the date of this announcement, the Company has declared and paid dividends of approximately RMB100 million (equivalent to approximately HKD109.7 million) for the financial year ended December 31, 2025, and has repurchased on the open market an aggregate of 162,609,000 Shares for approximately RMB328.9 million (equivalent to approximately HKD373.6 million). The Company plans to continue implementing the Shareholder Return Plan as part of its ongoing commitment to enhancing returns to its shareholders.

In view of its sound cash flow position and strong confidence in the future performance and long-term development prospects, the Company intends to continue conducting Share repurchases in 2026. The Company remains well positioned to continue implementing its Shareholder Return Plan and pursue further Share repurchases in the coming months (or as and when appropriate, instruct the trustee to acquire existing Shares on the open market for share incentive purposes), subject to market conditions and applicable regulatory requirements, as it believes that the prevailing trading price of the Shares does not fully reflect its intrinsic value. The Company also expects to progressively

increase cash dividend distributions for the financial years ending December 31, 2027 and 2028, as and when the trading price of the Shares more appropriately reflects their intrinsic value, with the aim of achieving annual dividend distributions equivalent to approximately 20% to 40% of the Company's annual non-IFRS adjusted earnings before interest, taxes, depreciation and amortization (“**non-IFRS adjusted EBITDA**”)¹ (“**pay-out rate**”). For illustrative purpose only, the non-IFRS adjusted EBITDA for the twelve months ended June 30, 2026 was approximately RMB602.9 million². Based on this illustrative figure and assuming the above Shareholder Return Plan had been in effect during the relevant period, the amount of dividend to be distributed under the Shareholder Return Plan would have ranged from approximately RMB120.6 million to RMB241.2 million. Such figures are provided for illustrative purposes only and should not be regarded as any guarantee or confirmation of any actual dividend entitlement, declaration or payment by the Company. In determining any increase in the pay-out rate, the Company will take into account, among other things, the ramp-up progress and operating performance of Shenzhen Zhongshan Obstetrics and Gynecology Hospital (深圳中山婦產醫院), the progress of other strategic initiatives and transactions, and the overall financial position and capital requirements of the Group.

Shareholders and potential investors of the Company are advised that the implementation of the Shareholder Return Plan together with any proposed dividend distribution or share repurchase are subject to the final decisions of the Board upon its careful deliberations and where applicable, the approval at the general meeting of the Company from time to time in accordance with the relevant requirements under the memorandum and articles of association of the Company and applicable laws and regulations.

Shareholders and potential investors of the Company are therefore advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Jinxin Fertility Group Limited
Dong Yang
Chief Executive Officer,
Acting Chief Financial Officer
and Executive Director

Hong Kong, October 2, 2026

¹ *Non-IFRS adjusted EBITDA is generally calculated with exclusions to, among other things, (i) ESOP expenses; (ii) impairment of goodwill and certain intangible assets related to the Group's business; (iii) impairment losses recognized under the expected credit loss model in respect of certain financial assets.*

² *The non-IFRS adjusted EBITDA for the twelve months ended June 30, 2026 was calculated based on (i) the non-IFRS adjusted EBITDA of approximately RMB491.1 million for the twelve months ended December 31, 2025, (ii) less the non-IFRS adjusted EBITDA of approximately RMB224.7 million for the six months ended June 30, 2025, and (iii) plus the non-IFRS adjusted EBITDA of approximately RMB336.5 million for the six months ended June 30, 2026. Such figure is subject to audit and may be subject to adjustments.*

As at the date of this announcement, the board of directors of the Company comprises Mr. Dong Yang, Dr. Lyu Rong and Dr. Geng Lihong, as executive directors; Mr. Zhong Yong, as chairman and non-executive director, and Ms. Hu Zhe, Ms. Yan Xiaoqing and Mr. Chen Shuyun, as non-executive directors; and Dr. Chong Yat Keung, Dr. Li Jianwei, Mr. Wang Xiaobo and Mr. Ye Changqing, as independent non-executive directors.

** For identification purposes only*